Compare stocks

APUS vs CAPR

Apimeds Pharmaceuticals US, Inc. and Capricor Therapeutics Inc

Compare the businesses

Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, a purified, pharmaceutical grade venom of the Apis mellifera, or honeybee for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company has a strategic alliance with University of Alabama for the development of ai² future labs program. The company was incorporated in 2020 and is based in Matawan, New Jersey.

Open APUS dashboard ↗

Capricor Therapeutics Inc

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Open CAPR dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

Sign in →

New to NexusTrade? Create a free account.

Choose another comparison ↗